Summary: Truxima is the first FDA-approved biosimilar version of rituximab (reference product, Rituxan) manufactured by Genentech.
Originally designated CT-P10 by its manufacturer, Celltrion, which submitted a biologic license application for approval via the 351(k) biosimilar pathway in June 2017. The Food and Drug Administration (FDA) rejected the application in April 2018. Celltrion resubmitted to FDA the following month. It was recommended for approval in October 2018 by the FDA’s Oncology Drug Advisory Committee, and approved in November 2018. The agent was launched in the US in November 2019. The drug received approval for its nononcology indications in December 2019.
About the Manufacturer
Celltrion was founded in 2002 in Incheon, South Korea. Its first biosimilar product was approved in 2013 by the European Medicines Agency, and Inflectra was first approved in the US in 2016. Celltrion has six other biosimilar products in development.
In October 2016, Celltrion and Teva formed a partnership, in which Teva would commercialize two biosimilars, Truxima and Herzuma (both of which are approved marketed) in the US.
News, Commentary, and Intelligence
Competitor Products and Manufacturer Analysis
Truxima is the first rituximab biosimilar to be approved by the FDA. The product entered the marketplace in November 2019.
Pfizer received approval for its agent Ruxience in July 2019; this agent began its marketing in January 2020. Boehringer Ingelheim and Sandoz both had biosimilars in Phase III development but made business decisions to not move forward with the products.
Rituximab Biosimilar(s) in Development
|Company Name||Product Name||Brand Name||Stage of Development|
Phase III trial expected to be completed in June 2019 for NHL
Phase III trial for rheumatoid arthritis was completed in October 2018
Met with FDA in July 2018 to finalize “ the most optimal pathway towards registering” in the US; Filed for EMA approval in June 2018
Truxima Now Available With Autoimmune Indications
(May 4, 2020) Partners Teva and Celltrion announced the launch of their biosimilar Truxima for two autoimmune indications (rhematoid arthritis and Wegener’s granulomatosis).
Pfizer Launches Ruxience, Announces Pricing for Upcoming Trazimera
Partners Teva/Celltrion Seek the Jump on Pfizer, Launch Their Rituximab Biosimilar Next Week
(November 8, 2019) When Pfizer announced its intention just more than a week ago to begin marketing its rituximab biosimilar Ruxience® in January 2020, industry watchers wondered when we might hear a response from its sole approved competitor. The wait was over quickly: Teva and Celltrion will begin shipping their own rituximab biosimilar Truxima® on November 11.
The Biosimilar Mabs Have It: FDA Approves Biosimilars for Adalimumab and Rituxumab
(July 24, 2019) On July 22, 2019, the Food and Drug Administration (FDA) announced the approval of Pfizer’s Ruxience, a biosimilar of rituximab. Compared with reference agent MabThera, this biosimilar proved to produce equivalent efficacy and safety in a phase 3 trial.
Pfizer Signs Patent Settlement With Roche on Rituximab Biosimilar
(March 25, 2019) An agreement was announced between Pfizer and Roche (Genentech), which concludes litigation over a key patent for Rixutan. This may affect when Pfizer decides on marketing the product.
Rituximab Biosimilar Approved by FDA for Cancer Treatment
(November 28, 2018) On November 28, 2018, the Food and Drug Administration (FDA) announced the approval of rituximab-abbs (Truxima™), produced by Celltrion and marketed by Teva. Approval for this rituximab biosimilar was overwhelmingly recommended by the FDA’s Oncology Drug Advisory Committee by a vote of 16-0 in October.
Sandoz Decides Against Marketing Rituximab Biosimilar in US
(October 30, 2018) Sandoz announced that it would halt its efforts to obtain approval for its biosimilar version of rituximab from the US Food and Drug Administration (FDA).
Celltrion's Rituximab Biosimilar Earns Positive FDA Review
(October 8, 2018) The information package released by reviewers for the Food and Drug Administration (FDA) indicates that a positive recommendation for Celltrion’s rituximab biosimilar is likely at the Advisory Committee meeting on October 10.
Celltrion Bounces Back, Resubmits for FDA Approval of Rituximab Biosimilar
(May 30, 2018) Anticipating that its issues with the Incheon, South Korea, manufacturing plant will be resolved, Celltrion has resubmitted its biologic license application for a rituximab biosimilar (CT-P10).
FDA Hands Sandoz a Rejection on Its Rituximab Biosimilar
(May 2, 2018) Sandoz announced today that the Food and Drug Administration (FDA) has decided not to approve its biosimilar version of the oncology biosimilar rituximab.
Teva and Celltrion Receive Rejections on Trastuzumab and Rituximab Biosimilars
(April 5, 2018) Celltrion and its partner Teva were dealt a significant blow today, as the Korean manufacturer announced that the latest two biosimilar candidates were rejected by the Food and Drug Administration.
Biosimilar Rituximab Under FDA Review
(July 5, 2017) Celltrion announced June 30, 2017 that it has submitted its 351(k) application to the Food and Drug Administration for approval of its biosimilar version of rituximab. This represents the first biosimilar application for rituximab, a monoclonal antibody to CD20..
Celltrion’s Rituximab Recommended for Approval in Europe
(January 3, 2017) Just weeks after Celltrion presented data at the American College of Rheumatology meeting demonstrating that its product CT-P10 is as safe and effective as Rituxan®for the treatment of rheumatoid arthritis (RA), the European Medicines Agency (EMA) received the recommendation to approve the product for use in the EU.
CT-P10 Rituximab Biosimilar Phase 3 Clinical Trial Results Announced
(September 28, 2016) The results of a phase 3 trial presented at the American College of Rheumatology meeting proved that a biosimilar version of Rituxan provided equivalent results over a 24-week study period compared with the originator product.